Systemic sclerosis & Raynaud's
Prospective evaluation of recombinant Herpes zoster vaccine in SSc: immunogenicity, safety and disease outcomes
Authors' conclusion
RZV was well tolerated. Despite the high seroconversion rate, the immune response was significantly lower in magnitude compared with the controls, without triggering DA or worsening PROMs.
Study context
- Population
- Immunosuppressed patients with SSc (47.4% diffuse/52.6% limited) and healthy controls
- Participants
- 76 vs 304
- Comparison
- Immunosuppressed SSc patients vs healthy controls, both receiving two recombinant zoster vaccine (RZV) doses
- SScn = 76
- CGn = 304reference
- Primary endpoint
- Humoral immune response to RZV (anti-glycoprotein-E antibodies)
- Follow-up
- 6 weeks post-second dose
Methodological detailsdouble-blind, placebo-controlled, sub-analysis
- Double-blind
- Placebo-controlled
- Sub-analysis
Primary result
As reported in the abstract
Humoral response
P = 0.001
Further findings
| Outcome | SSc | CG | P value |
|---|---|---|---|
| GMC of anti-glycoprotein-E antibodies · 6 weeks post-second dose | 5.81 | 12.6 | P < 0.001 |
| Factor increase (FI) · 6 weeks post-second dose | 31.0 | 59.4 | P < 0.001 |
Cell-mediated immunogenicity
- Comparable cell-mediated immunogenicity (CMI)
- P > 0.05
Predictors of vaccine response
- Disease subtypes, demographic factors, immunosuppressive therapies or nutritional status did not predict impaired vaccine response
- P > 0.05
Disease activity (DA) and patient-reported outcome measures (PROMs)
- DA and PROMs outcomes remained stable
- P > 0.05
Safety
Local adverse events
P = 0.024
Systemic reactions
P = 0.712
Original publication
Prospective evaluation of recombinant Herpes zoster vaccine in SSc: immunogenicity, safety and disease outcomes. Rheumatology (Oxford). Published 8 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →